Skip to main content

GeneProt, Duke, and Novartis Study Proteomics of Heart Disease

NEW YORK, Sept. 4-Researchers at GeneProt and Novartis are working with cardiologists at Duke University Medical Center to characterize distinctive protein expression patterns in heart disease patients, the university said yesterday.

 

The researchers are using an "industrial-scale" approach to protein analysis in order to uncover the subtle differences between protein levels in healthy people and people with coronary artery disease.

 

Duke has identified appropriate patients and provided access to clinical samples through its large database of cardiovascular patients. GeneProt is analyzing proteins of interest, and synthesizing some of them for further study by researchers at Novartis.

 

The collaborators have identified 106 matched healthy controls and heart disease patients, and plan to analyze a total of six liters of blood from each group. These large volumes of blood are necessary, according to the researchers, in order to accurately identify proteins relevant to disease.

 

At Duke, the study is led by Chris Granger, a cardiologist at the university's clinical research institute.

 

For further information, see the press release.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.